Welcome to our dedicated page for Drugs Made In Amer Acqutn SEC filings (Ticker: DMAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Drugs Made In America Acquisition Corp. (DMAA) provides direct access to the company’s regulatory reports as a Cayman Islands blank check issuer listed on The Nasdaq Stock Market LLC. These filings offer detailed insight into its corporate governance, officer appointments, consulting arrangements, and reporting status.
Key documents for Drugs Made In America Acquisition Corp. include current reports on Form 8-K, which disclose material events. One Form 8-K describes the resignation of the company’s Chief Financial Officer and principal financial and accounting officer and notes that the resignation was not due to any disagreement with the company. The same filing outlines the appointment of a new principal financial and accounting officer and a Master Services Agreement with Titan Advisory Services LLC, including compensation terms and share grants.
Another important filing type is the Form 12b-25 (NT 10-Q). DMAA’s NT 10-Q for the quarter ended September 30, 2025, explains why its Quarterly Report on Form 10-Q could not be filed by the deadline, citing the need for additional time to complete financial statements and obtain necessary review and signatures. The notification also confirms that all other required periodic reports had been filed and that no significant change in results of operations was anticipated for that quarter.
On this page, users can review Forms 10-K, 10-Q, 8-K, and NT 10-Q as they become available, along with any related exhibits. AI-powered summaries help explain the significance of these documents, highlight key terms such as officer changes, consulting agreements, and filing delays, and make it easier to interpret the technical language of SEC reports for Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. (DMAA) reported net income of $2.18 million for the quarter and $5.73 million for the nine months ended September 30, 2025, driven almost entirely by $6.45 million of interest earned on the cash and investments held in its trust account. Operating expenses remain modest, with general and administrative costs of $263,703 for the quarter and $726,547 year-to-date as the SPAC continues to search for a pharmaceutical-sector business combination.
The company’s balance sheet shows $237.6 million of cash and investments in the trust account, backing 23,000,000 ordinary shares subject to redemption at $10.33 per share, while cash outside the trust is only $717 and working capital shows a deficit of $428,415. Management discloses that the mandatory liquidation deadline—15 months after the IPO closing, or up to 21 months if extensions are funded—raises substantial doubt about the company’s ability to continue as a going concern if no business combination is completed within this “Combination Period.”
Drugs Made In America Acquisition Corp. (DMAA) reported a change in its chief financial officer role. On October 8, 2025, CFO and principal financial and accounting officer Glenn Worman resigned, and he stated that his departure was not due to any disagreement with the company’s operations, policies, or practices. On November 17, 2025, the company appointed Saleem Elmasri as its new CFO and principal financial and accounting officer, providing his services through a Master Services Agreement with Titan Advisory Services LLC. Titan will receive $42,000 per year, or $3,500 per month, for Mr. Elmasri’s CFO services, and Mr. Elmasri will receive 100,000 ordinary shares, either granted by the company or transferred by the CEO. He brings about 20 years of financial and consulting experience, including senior roles at PwC and several advisory firms.
Drugs Made In America Acquisition Corp. (DMAA) has filed a Form 12b-25 to notify the SEC that it will be late filing its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company explains that the financial statements for this quarter were not completed in time to obtain the necessary internal review and required signatures before the normal filing deadline. This notice is intended to provide a short grace period while the report is finalized and formally submitted.
FAQ
What is the current stock price of Drugs Made In Amer Acqutn (DMAA)?
What is the market cap of Drugs Made In Amer Acqutn (DMAA)?
